Compounds > adam ii
Page last updated: 2024-12-08

adam ii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ADAM II: an alkenyldiarylmethane compound; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID393516
CHEMBL ID294840
SCHEMBL ID14041153
MeSH IDM0291093

Synonyms (25)

Synonym
alkenyldiarylmethanes (adam) 22
methyl 3,3-dichloro-4,4-dimethoxy-5,5-bis(methoxycarbonyl)-6,6-diphenylhexenoate
bdbm2753
methyl 3-chloro-5-{1-[3-chloro-4-methoxy-5-(methoxycarbonyl)phenyl]-6-methoxy-6-oxohex-1-en-1-yl}-2-methoxybenzoate
chembl294840 ,
nsc695574
204864-54-0
methyl 3-chloro-5-[1-(3-chloro-4-methoxy-5-methoxycarbonyl-phenyl)-6-methoxy-6-oxo-hex-1-enyl]-2-methoxy-benzoate
adam ii
methyl 3',3''-dichloro-4',4''-dimethoxy-5',5''-bis(methoxycarbonyl)-6,6-diphenylhexenoate
benzoic acid, 3,3'-(6-methoxy-6-oxo-1-hexenylidene)bis[5-chloro-6-methoxy-, dimethyl ester
1,3''-dicarbomethoxy-5',5''-dichloro-4',4''-dimethoxydiphenyl)-5-hexenoate
nsc-695574
methyl 3-chloro-5-[1-(3-chloro-4-methoxy-5-methoxycarbonylphenyl)-6-methoxy-6-oxohex-1-enyl]-2-methoxybenzoate
dimethyl 3,3'-(6-methoxy-6-oxohex-1-ene-1,1-diyl)bis(5-chloro-6-methoxybenzoate)
nsc 695574
unii-kxwjvsivfb
adam-ii
kxwjvsivfb ,
benzoic acid, 3,3'-(6-methoxy-6-oxo-1-hexenylidene)bis(5-chloro-6-methoxy-, dimethyl ester
SCHEMBL14041153
DTXSID00174457
3,3'-(6-methoxy-6-oxo-1-hexenylidene)bis(5-chloro-6-methoxy-, dimethyl ester, benzoic acid
3,3'-(6-methoxy-6-oxo-1-hexen-1-ylidene)bis(5-chloro-6-methoxy-, 1,1'-dimethyl ester, benzoic acid
AKOS030594689

Research Excerpts

Overview

ADAM II is a non-nucleoside reverse transcriptase inhibitor. It has an IC50 of 0.3 microM with poly(rC) oligo(dG) as the template/primer.

ExcerptReferenceRelevance
"ADAM II is a non-nucleoside reverse transcriptase inhibitor, displaying an IC50 of 0.3 microM with poly(rC) oligo(dG) as the template/primer."( Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
Casimiro-Garcia, A; Cushman, M; Rice, WG; Williamson, K, 1998)		1.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.62000.00060.91418.3200AID1795426; AID1795427; AID1795429; AID1795431
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.70000.00011.076810.0000AID197954; AID197957; AID198107; AID198415; AID199088; AID298059; AID317728; AID82960
Protease Human immunodeficiency virus 1IC50 (µMol)100.00000.00010.22487.3200AID162387
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (137)

Assay IDTitleYearJournalArticle
AID45005The compound is evaluated for the fold resistance.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46421The compound is evaluated for the activity against HIV-1 NL4-3, L100I mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID44999The compound is evaluated for the activity against HIV-1 IIIB, wild - type mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45002The compound is evaluated for the activity against calo ( calanolide resistant), T139I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46429The compound is evaluated for the inhibitory activity against HIV-1 IIIB, wild-type laboratory adapted strain in CEM-SS.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID83089Inhibition of cytopathic effect of HIV-1 strain wild type enzyme NL4-3 in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID125202The compound is evaluated for the inhibitory activity against HIV-1 Ba-L, monocyte-tropic in Mono/Mac cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID154774Antiviral activity against WEJO virus strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46380Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154773Antiviral activity against TEKI virus strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID317729Antiviral activity against HIV1RF infected in human CEM-SS cells2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID46425The compound is evaluated for the activity against HIV-1 NL4-3, V179D mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46417The compound is evaluated for the activity against HIV-1 NL4-3, 4XAZT/Y181C (AZT resistant) mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID154772Antiviral activity against SLKA virus strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46431The compound is evaluated for the fold resistance.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID154787Antiviral activity against subtype isolate F strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45695Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation Y188C in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID298065Metabolic stability in rat plasma2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID46383Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45694Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation Y181C resistant to AZT in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45689Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation L74V in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46081Ratio of CC50/EC50 was determined2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46377Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46382Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID155110The compound is evaluated for the inhibitory activity against HIV-1, clade D in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID105315Effective concentration required to inhibit cytopathicity of HIV-1(IIIB) in MT-4 cells2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
AID154785Antiviral activity against subtype isolate E strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154777Antiviral activity against subtype isolate A strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID317730Antiviral activity against HIV13B infected in human MT4 cells2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID155108The compound is evaluated for the inhibitory activity against HIV-1, clade B in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45173Concentration required for cytotoxicity against mock infected CEM-SS cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46418The compound is evaluated for the activity against HIV-1 NL4-3, A98G mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID317731Antiviral activity against HIV2ROD infected in human MT4 cells2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID162387The compound is evaluated for the inhibitory against HIV -1 protease, a 17% inhibition of HIV-1 protease was observed at a concentration of 100 uM1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID12678Half-life in rat plasma2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
AID45869Fold resistance of HIV-1 RT containing the specified mutation V108I in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45721Fold resistance of HIV-1 RT containing the specified mutation A98G in CEM-SS cells; NC=No significant change in sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46423The compound is evaluated for the activity against HIV-1 NL4-3, V106A mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46378Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID317732Cytotoxicity against human HIV1RF infected CEM-SS cells by MTT assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID45873Fold resistance of HIV-1 RT containing the specified mutation Y181C in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID47659The compound is evaluated for the activity against 129/cost (costatolide resistant), V108I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID298063Cytotoxicity against human CEM-SS cells by MTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID154775Antiviral activity against multi drug resistant MDR 769 strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154779Antiviral activity against subtype isolate B strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45555Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation 4X resistant to AZT in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID298061Antiviral activity against HIV1 3B in human MT4 cells by XTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID45692Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation V179D in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46979The compound is evaluated for the cytotoxic concentration for the mock-infected CEM cells1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID235026The compound is evaluated for the therapeutic index, which is the CC50 divided by the EC50.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46379Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46416The compound is evaluated for the activity against HIV-1 NL4-3, 4XAZT/L100I (AZT resistant) mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID235245Therapeutic index was determined for the compound as CC50/EC501999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46375Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID91428The compound is evaluated for the inhibitory against HIV -1 integrase. NI indicates no inhibition at 100 uM conc.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45875Fold resistance of HIV-1 RT containing the specified mutation Y181C resistant to AZT in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID155112The compound is evaluated for the inhibitory activity against HIV-1, clade F in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46374Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46427The compound is evaluated for the activity against HIV-1 NL4-3, Y188C mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45718Fold resistance of HIV-1 RT containing the specified mutation 4X resistant to AZT in CEM-SS cells; NC=No significant change in sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID44998The compound is evaluated for the activity against HEPT ((Hydroxyethoxy) methyl (phenylthio)thymine resistant), P236L mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID155107The compound is evaluated for the inhibitory activity against HIV-1, clade A in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45877Fold resistance of HIV-1 RT containing the specified mutation Y188C in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID154781Antiviral activity against subtype isolate C strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID155113The compound is evaluated for the inhibitory activity against HIV-1 ROJO, wild-type clinical isolate in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID82960Compound was tested for the inhibition of HIV-1 reverse transcriptase1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
AID46415The compound is evaluated for the activity against HIV-1 NL4-3, 4XAZT (AZT resistant) mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46420The compound is evaluated for the activity against HIV-1 NL4-3, K103N mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID317728Inhibition of HIV1 reverse transcriptase2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID298060Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID46424The compound is evaluated for the activity against HIV-1 NL4-3, V108I mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID298062Antiviral activity against HIV2 ROD in human MT4 cells by XTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID45687Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation L100I in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID155111The compound is evaluated for the inhibitory activity against HIV-1, clade E in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID198415The compound is evaluated for the inhibitory against HIV -1 reverse transcriptase with rAdT as the template primer.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45725Fold resistance of HIV-1 RT containing the specified mutation K103N in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45691Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation V108I in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID199088Inhibitory activity against HIV-1 Reverse Transcriptase with rCdG as the template primer2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID40034Antiviral activity against Ba-L monocyte tropic isolate strain in monocyte2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID298064Cytotoxicity against human MT4 cells by MTT assay2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID154783Antiviral activity against subtype isolate D strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46433The compound is evaluated for the fold resistance; S - Enhanced sensitivity1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45686Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation K103N in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID146804Inhibition of HIV-1 Nucleocapsid protein p7 (no inhibition at 25 uM)1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46249Compound was tested for the prevention of cytopathic effect of HIV-1 RF in CEM-SS cells1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
AID154771Antiviral activity against ROJO virus strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45000The compound is evaluated for the activity against OC (Oxathiin carboxanilide resistant), L100I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45688Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation L100I resistant to AZT in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46083Compound was tested for cytotoxicity in uninfected CEM-SS cells1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
AID105317Effective concentration required to inhibit cytopathicity of HIV-2(ROD) in MT-4 cells2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
AID46430The compound is evaluated for the inhibitory activity against HIV-1 RF, wild-type laboratory adapted strain in CEM-SS.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID1331273Inhibition of HIV-1 reverse transcriptase assessed as reduction in [32P]GTP incorporation using poly(rC)/oligo(dG) as template/primer by beta counting method2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone derivatives.
AID47661The compound is evaluated for the activity against DPS ( Diphenyl sulfone resistant), Y181C mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45001The compound is evaluated for the activity against TSAO/cost (costatolide resistant), K101E mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45003The compound is evaluated for the activity against cost, Y188H mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46376Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154789Antiviral activity against subtype isolate G strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46432The compound is evaluated for the fold resistance; NC - No significant change in sensitivity1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45864Fold resistance of HIV-1 RT containing the specified mutation L74V in CEM-SS cells; NC=No significant change in sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID317734Inhibition of tubulin polymerization after 20 mins2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID298059Inhibition of HIV1 reverse transcriptase2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID46617Therapeutic index (CC50/EC50) was determined1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
AID125201The compound is evaluated for the inhibitory activity against HIV-1 ADA, monocyte-tropic in Mono/Mac cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45847Concentration inhibiting 50% of mock-infected CEM cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46426The compound is evaluated for the activity against HIV-1 NL4-3, Y181C mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45684Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation A98G in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45863Fold resistance of HIV-1 RT containing the specified mutation L100I resistant to AZT in CEM-SS cells; S=Enhanced sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID317733Cytotoxicity against mock-infected human MT4 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID4535150% inhibitory concentration for cytopathicity of HIV-1 RF in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID197954Inhibition of HIV-1 Reverse transcriptase using poly-(ra)-oligo(dt) as the template primer.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45867Fold resistance of HIV-1 RT containing the specified mutation V106A in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45690Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation V106A in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID45693Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation Y181C in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID197957Inhibition of HIV-1 Reverse transcriptase using poly-(rc)-oligo(dg) as the template primer.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID155109The compound is evaluated for the inhibitory activity against HIV-1, clade C in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46384Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46385Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID104801Evaluated for cytotoxicity in mock-infected MT-4 cells2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
AID45697Inhibitory concentration for cytopathicity of HIV-1RF in CEM-SS cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID45871Fold resistance of HIV-1 RT containing the specified mutation V179D in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID155114The compound is evaluated for the inhibitory activity against HIV-1 TEKI, wild-type clinical isolate in PBMC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46261Inhibitory concentration for cytopathicity of HIV-1 in CEM-SS cells1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45004The compound is evaluated for the activity against thiazol (thiazolobenzimidazole resistant), T139I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45685Inhibition of cytopathic effect of HIV-1 RT containing the specified mutation K101E in CEM-SS cells.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID46381Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID154791Antiviral activity against subtype isolate O strain in PBLs (peripheral blood lymphocytes)2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID46419The compound is evaluated for the activity against HIV-1 NL4-3, K101E mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45861Fold resistance of HIV-1 RT containing the specified mutation L100I in CEM-SS cells; S=Enhanced sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID47660The compound is evaluated for the activity against 3TC, M184I mutation in reverse transcriptase in CEM-CC cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46422The compound is evaluated for the activity against HIV-1 NL4-3, L74V mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID46428The compound is evaluated for the activity against HIV-1 NL4-3, wild - type mutation in reverse transcriptase in CEM-SS cells.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID198107Inhibitory activity against human immunodeficiency virus (HIV) - 1 reverse transcriptase with rCdG as the template primer1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
AID45723Fold resistance of HIV-1 RT containing the specified mutation K101E in CEM-SS cells; NC=No significant change in sensitivity1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID1795429HIV-1 RT Assay from Article 10.1016/s0968-0896(01)00282-6: \\Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.\\2002Bioorganic & medicinal chemistry, Feb, Volume: 10, Issue:2
Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.
AID1795427HIV-1 RT Assay from Article 10.1021/jm010212m: \\The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibi2001Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1795431HIV-1 RT Assay from Article 10.1021/jm990343b: \\Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.\\1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
AID1795426HIV-1 RT Assay from Article 10.1021/jm9800595: \\New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.\\1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (33.33)18.2507
2000's5 (55.56)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.46 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index111.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.7230cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.0410alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.7230azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		2.4820acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
fosbretabulin
[no description available]		2.0410stilbenoid
ConditionIndicatedRelationship StrengthStudiesTrials